CompanyOBXNasdaqCambridge, MA

Obsidian Therapeutics, Inc.

Obsidian Therapeutics develops engineered TIL cell therapies for solid tumors using its cytoDRiVE® technology, which regulates protein function with small-molecule drugs.

Stories only

SEC EDGAR ClinicalTrials.gov obsidiantx.com

S-1Aug 28Latest SEC filing

Aug 28Latest story

August 2026

Obsidian Therapeutics files S-1 for resale of 29.16 million shares post-merger with Galera

Aug 28FinancingObsidian Therapeutics, Inc.

Obsidian Therapeutics completes merger with Galera, closes $350 million private placement

Aug 3FinancingObsidian Therapeutics, Inc.